Celcuity Q4 Net Loss Hits $177M as R&D Costs Surge $40.8M
Celcuity reported a full-year 2025 net loss of $177 million, up significantly from 2024, as R&D expenses rose by $40.8 million driven by employee, consulting, and launch preparations. The FDA has granted priority review to its gedatolisib NDA and cash reserves of $441.5 million are expected to fund operations through 2027.
1. 2025 Financial Performance
Celcuity recorded a full-year 2025 net loss of $177 million, driven by a $40.8 million increase in R&D expenses due to higher employee costs, consulting fees, and commercial launch-related activities. This marks a sharp rise from the previous year’s results.
2. Clinical and Regulatory Developments
The FDA has accepted the new drug application for gedatolisib with priority review status, while exact timing and details for the PIK3CA mutant cohort readout in the VICTORIA-1 trial remain uncertain pending top-line data disclosure at an upcoming medical conference.
3. Commercial Launch Preparation and Cash Runway
With $441.5 million in cash and investments, Celcuity expects to fund operations through 2027 and has built a sales force, engaged key healthcare decision-makers, and plans a fourth-quarter MAA submission along with potential global launch partnerships.